MUSASHIAI
MusashiAI, a JV between Israeli SixAI and Japanese Musashi Seimitsu (a Honda Motor Corporation affiliate company), is announcing the commercial availability of its autonomous visual quality control inspector, autonomous forklift driver and disruptive mobile robots fleet management system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200727005008/en/
Live trials from December 2019 confirm that MusashiAI’s unique autonomous robotic visual inspector exceeds the speed, accuracy, and stamina of human workers in a world-first technological advance. The autonomous forklift driver exceeds modelled expectations with unparalleled efficiency, cost-effectiveness and safety standard, using unique technology that combines ‘birds-eye’ view cameras above the factory floor and a central processing unit.
In additions to its initial commitment with advance payment of $10 million, Musashi Seimitsu is willing to expand the deployment of MusashiAI’s autonomous quality control inspectors and autonomous forklift drivers in its factories globally, subject to the company meetings certain development milestones.
The company has also secured a POC for the quality control inspector with one of the world's largest bearing manufacturers and three POCs for the autonomous forklift drivers and central management system with leading Israeli retail and FMCG groups starting Q4 this year. These agreements mark the first time the robots are being tested outside of the Musashi Seimitsu group.
An advanced form of deep learning which parallels the way the human brain absorbs and assimilates information was central to MusashiAI’s latest robotic models. Redeploying and switching robots between tasks is now much easier. These improvements are which the company anticipates will be essential for many socially-distanced industrial settings amidst the on-going COVID-19 pandemic.
Ran Poliakine, co-founder of MusashiAI said:
“Our vision is that the robots integrate easily onto production floors where there will still be some human workers, but others will be released from the drudgery of visual inspection and forklift driving. To our knowledge, no-one else offers visual robots which surpass the skills of human workers as ours do. Our OPEX model means clients can deploy robots when and where they need them, without extensive CAPEX.
“The interest from Musashi Seimitsu coupled with our latest finalised POC trials with a world-leading manufacturer and three leading Israeli logistics companies is a great sign of confidence in our technology and the gifts it brings to the future of humanity. I am excited about the company’s next steps.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005008/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Original “Titanic Cherub” From James Cameron’s Epic Film Heads to Auction December 9 & 1024.11.2025 21:48:00 CET | Press release
Iconic Hollywood Artifact Indelibly Linked with “Jack & Rose” Portrayed by Kate Winslet and Leonardo DiCaprio One of the most recognizable and beloved set pieces from James Cameron’s Titanic heads to auction on December 9 &10 —the original Grand Staircase Cherub, seen in multiple scenes of the 1997 blockbuster, including the pivotal moment when Jack and Rose meet in front of the First Class Dining Room and the climactic moment when the Atlantic Ocean bursts through the skylight and floods the staircase, and cherub. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124056883/en/ The iconic “cherub” with Leonardo DiCaprio & Kate Winslet in James Cameron’s “TITANIC”. The ornate fixture—crafted for the full-scale recreation of Titanic’s Grand Staircase—was gifted by the production to Martin Biallas, CEO of SEE Global Entertainment, whose immersive exhibitions have brought the world’s most famous ship to millions of fans. It now
Access Advance Announces Major Growth in Its HEVC and VVC Patent Pools24.11.2025 16:10:00 CET | Press release
Access Advance LLC today announced significant expansions of both its HEVC Advance and VVC Advance Patent Pools during the second and third quarters of 2025, underscoring continued industry confidence in the company's balanced and transparent approach to video codec licensing. This growth follows the successful January 2025 launch of Access Advance's Video Distribution Patent ("VDP") Pool, demonstrating the company's expanding role in comprehensive video codec patent licensing solutions. Among the many highlights, Sharp Corporation joined the HEVC Advance Patent Pool as a Licensor, bringing valuable intellectual property assets to the pool's already extensive patent portfolio. Additionally, Huawei Technologies Co., Ltd., already an HEVC Advance Licensor and Licensee, expanded its collaboration with Access Advance by joining the VVC Advance Patent Pool as a Licensee. HP Inc. also expanded its license to include the VVC Advance Patent Pool after previously joining HEVC Advance in 2024, w
Microsize and Schedio Group to Acquire Lonza’s Micro-Macinazione Site in Switzerland24.11.2025 15:05:00 CET | Press release
Microsize, a leading CDMO specializing in particle size reduction and control technologies, today announced it has signed an agreement to acquire Micro-Macinazione (Mic Mac), a dedicated micronization facility in Monteggio, Switzerland, from Lonza. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124545344/en/ The agreement represents Microsize’s second acquisition from Lonza, following the successful 2022 divestment of its Quakertown, Pennsylvania site. In this transaction, Schedio Group – a Swiss-based provider of jet mills, isolators, spray dryers, and engineering services – is investing alongside Microsize to strengthen and localize its operational base in Europe, advancing a shared vision to lead the next generation of integrated particle engineering solutions. With more than 30 years of experience, Mic Mac has served the pharmaceutical industry with proven GMP-compliant jet milling and micronization capabilities for b
Hytera to Debut S1 E at PMRExpo 202524.11.2025 14:17:00 CET | Press release
Hytera, a leading global provider of critical communications technologies and solutions, today introduced the S1 E, a business-ready, palm-sized two-way radio designed specifically for the retail sector, expanding the portfolio of S Series and providing one more option for retail users to choose for their daily operations. The S1 E will make its debut at PMRExpo, the Europe's premier trade fair for secure, mission- and business-critical communication, taking place from November 25th to 27th, 2025, at Koelnmesse in Cologne, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124768341/en/ Hytera New Released Licence-free Analogue Business Radio S1 E Adhering to the S Series’ signature design language, the S1 E combines a stylish, modern, and minimalist aesthetic with practical functionality. Weighing under 85g, the S1 E provides all-day wearing comfort without tugging or weighing down uniforms. Key enhancements and sta
Merck Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis24.11.2025 14:00:00 CET | Press release
Cladribine capsules have the potential to be the first oral treatment for people living with rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia GravisCladribine capsules has received Fast Track designation and Orphan Drug Designation by the US FDAMerck has established an MG patient council to provide insights on how to best meet the needs of patients in the gMG rare disease community Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for cladribine capsules for the treatment of the rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia Gravis (gMG). In June 2023, the FDA granted Orphan Drug Designation for cladribine capsules for the treatment of gMG. In addition, the Company is actively collaborating with patient organizations and Ad Scientiam, a medical technology company, to support a patient-directed approach to the future management of gMG. If approved
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom